Yiwei Li from 10606 Maplecrest Ln, Rockville, MD 20854, age 55

Us Patents

Inhibitors Of Akt Activity
view source
US Patent:

7544677, Jun 9, 2009
Filed:

Aug 19, 2005
Appl. No.:

11/659606
Inventors:

Mark T. Bilodeau - Lansdale PA, US
Nicholas D. P. Cosford - San Diego CA, US
John C. Hartnett - Philadelphia PA, US
Yiwei Li - San Diego CA, US
Jun Liang - Palo Alto CA, US
Peter J. Manley - Harleysville PA, US
Lou Anne Neilson - Sellersville PA, US
Tony Siu - Brookline MA, US
Zhicai Wu - Quakertown PA, US
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

A61K 31/541
A61K 31/5355
A61K 31/519
C07D 471/04
C07D 519/00
A61P 35/00
US Classification:

51421021, 5142641, 51421706, 5142285, 5142342, 540220, 540481, 540600, 544 582, 544 90, 544127, 544277, 544279, 546194, 546288, 546286
Abstract:

The present invention is directed to compounds which contain substituted 5-deazapteridine moieties which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

Inhibitors Of Akt Activity
view source
US Patent:

7910561, Mar 22, 2011
Filed:

Dec 9, 2005
Appl. No.:

11/792121
Inventors:

Jeannie M. Arruda - San Diego CA, US
Brian T. Campbell - San Diego CA, US
Nicholas D. P. Cosford - San Diego CA, US
Jacob M. Hoffman - Lansdale PA, US
Essa H. Hu - Camarillo CA, US
Mark E. Layton - Harleysville PA, US
Yiwei Li - Ambler PA, US
Jun Liang - Palo Alto CA, US
Kevin J. Rodzinak - Schwenksville PA, US
Tony Siu - Brookline MA, US
Brian A. Stearns - San Diego CA, US
Lida R. Tehrani - San Diego CA, US
Mark T. Bilodeau - Lansdale PA, US
Peter J. Manley - Harleysville PA, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A01N 43/04
A01N 43/58
A01N 43/42
A61K 31/541
A61K 31/70
A61K 31/50
A61K 31/495
A61K 31/52
C09B 25/00
C07D 487/00
C07D 491/00
C07H 15/00
US Classification:

514 43, 51421021, 514249, 51426322, 514314, 536 292, 544277, 544350, 546173
Abstract:

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.

5-Lipdxygenase-Activating Protein (Flap) Inhibitors
view source
US Patent:

7977359, Jul 12, 2011
Filed:

Oct 27, 2006
Appl. No.:

11/553946
Inventors:

John H. Hutchinson - La Jolla CA, US
Petpiboon Peppi Prasit - Rancho Santa Fe CA, US
Mark Moran - Orinda CA, US
Jillian F. Evans - Carlsbad CA, US
Brian Andrew Stearns - San Diego CA, US
Jeffrey Roger Roppe - Temecula CA, US
Yiwei Li - San Diego CA, US
Jasmine Eleanor Zunic - San Diego CA, US
Jeannie M. Arruda - La Jolla CA, US
Nicholas Simon Stock - San Diego CA, US
Mustapha Haddach - San Diego CA, US
Assignee:

Amira Pharmaceuticals, Inc. - San Diego CA
International Classification:

A61K 31/4439
C07D 401/14
US Classification:

514333, 546256
Abstract:

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

Inhibitors Of Akt Activtiy
view source
US Patent:

8008317, Aug 30, 2011
Filed:

Jun 7, 2006
Appl. No.:

11/921352
Inventors:

Donna J. Armstrong - Harleysville PA, US
Essa H. Hu - Camarillo CA, US
Mark E. Layton - Harleysville PA, US
Yiwei Li - San Diego CA, US
Jun Liang - Palo Alto CA, US
Kevin J. Rodzinak - Schwenksville PA, US
Michael J. Rossi - Limerick PA, US
Philip E. Sanderson - Valley Forge PA, US
Jiabing Wang - Chalfont PA, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 31/437
A61K 31/4375
C07D 471/14
C07D 471/16
US Classification:

514290, 546 81
Abstract:

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

Quinolone Neuropeptide S Receptor Antagonists
view source
US Patent:

8389720, Mar 5, 2013
Filed:

Nov 3, 2009
Appl. No.:

13/127898
Inventors:

James C. Barrow - Arnold MD, US
Mark T. Bilodeau - Harleysville PA, US
Christopher D. Cox - Harleysville PA, US
John C. Hartnett - Philadelphia PA, US
Nathan R. Kett - Franklin TN, US
Yiwei Li - Lower Gwynedd PA, US
Peter J. Manley - Harleysville PA, US
Jeffrey Melamed - North Wales PA, US
William D. Shipe - Chalfont PA, US
B. Wesley Trotter - Newton Highlands MA, US
Amy Zartman - Philadelphia PA, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 31/551
A61K 31/5355
A61K 31/497
A61K 31/519
A61K 31/4412
A61K 31/4704
C07D 243/08
C07D 413/14
C07D 471/04
C07D 401/14
C07D 401/12
C07D 405/14
US Classification:

544218, 5142352, 51425307, 5142641, 514306, 514312, 540575, 544138, 544279, 544360, 544363, 546157
Abstract:

The present invention is directed to quinolone compounds which are antagonists of neuropeptide S receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which the neuropeptide S receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the neuropeptide S receptor is involved.

5-Lipoxygenase-Activating Protein (Flap) Inhibitors
view source
US Patent:

8399666, Mar 19, 2013
Filed:

Oct 30, 2006
Appl. No.:

12/089707
Inventors:

John H. Hutchinson - La Jolla CA, US
Petpiboon Peppi Prasit - Rancho Santa Fe CA, US
Mark Moran - Orinda CA, US
Jillian F. Evans - San Diego CA, US
Brian Andrew Stearns - San Diego CA, US
Jeffrey Roger Roppe - Temecula CA, US
Yiwei Li - Lower Gwynedd PA, US
Jasmine Eleanor Zunic - San Diego CA, US
Jeannie M. Arruda - San Diego CA, US
Nicholas Simon Stock - San Diego CA, US
Mustapha Haddach - San Diego CA, US
Assignee:

Panmira Pharmaceuticals, LLC - San Diego CA
International Classification:

A61P 9/00
A61P 11/00
A61P 29/00
C07D 401/14
C07D 413/14
C07D 417/14
US Classification:

544238, 544333, 544405, 546152, 546256, 5462697, 548143
Abstract:

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

5-Lipoxygenase-Activating Protein (Flap) Inhibitors
view source
US Patent:

8546431, Oct 1, 2013
Filed:

Oct 30, 2012
Appl. No.:

13/663622
Inventors:

Petpiboon Peppi Prasit - Rancho Santa Fe CA, US
Mark Moran - Orinda CA, US
Jillian F. Evans - San Diego CA, US
Yiwei Li - Lower Gwynedd PA, US
Jeannie M. Arruda - San Diego CA, US
Assignee:

Panmira Pharmaceuticals, LLC - San Diego CA
International Classification:

C07D 401/14
US Classification:

514333, 51425505
Abstract:

A method for treating a human comprises administering a therapeutically effective amount of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid or a pharmaceutically acceptable salt or a pharmaceutically acceptable N-oxide thereof, to the human in need.

5-Lipoxygenase-Activating Protein (Flap) Inhibitors
view source
US Patent:

20070219206, Sep 20, 2007
Filed:

May 4, 2007
Appl. No.:

11/744555
Inventors:

John Hutchinson - La Jolla CA, US
Petpiboon Prasit - Rancho Santa Fe CA, US
Mark Moran - Orinda CA, US
Jillian Evans - Carlsbad CA, US
Brian Stearns - San Diego CA, US
Jeffrey Roppe - Temecula CA, US
Bowei Wang - San Diego CA, US
Yen Truong - San Diego CA, US
Yiwei Li - San Diego CA, US
Jasmine Zunic - San Diego CA, US
Jeannie Arruda - San Diego CA, US
Nicholas Stock - San Diego CA, US
Mustapha Haddach - San Diego CA, US
Thomas Seiders - San Diego CA, US
Jill Scott - San Diego CA, US
Assignee:

AMIRA PHARMACEUTICALS, INC. - San Diego CA
International Classification:

A61K 31/506
A61K 31/501
A61K 31/497
A61K 31/498
A61K 31/4709
A61K 31/4745
A61K 31/4439
A61K 31/42
A61K 31/428
A61K 31/404
C07D 413/02
C07D 403/02
US Classification:

514249000, 514255050, 514252060, 514337000, 514256000, 514378000, 514303000, 514365000, 514367000, 514314000, 544238000, 544333000, 544284000, 544405000, 514406000, 546169000, 546118000, 548159000, 546277100, 544353000, 548364400, 548455000, 548247000
Abstract:

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

Isbn (Books And Publications)

Non-Classical Problems In The Theory Of Elastic Stability: Deterministic, Probabilistic And Anti-Optimization Approaches
view source
Author:

Yiwei Li
ISBN #:

0521020107

Non-Classical Problems In The Theory Of Elastic Stability
view source
Author:

Yiwei Li
ISBN #:

0521782104

Resumes

Yiwei Li

view source

Yiwei Li

view source

Yiwei Li

view source

Sales Executive At Sheraton

view source

Position:

Sales Executive at Sheraton

Location:

Hangzhou, Zhejiang, China

Industry:

Hospitality

Work:

Sheraton - Hangzhou, Zhejiang, China since Mar 2012
Sales Executive
Hyatt Regency - Hangzhou Oct 2011 - Feb 2012
Concierge
Hotel Phillips Aug 2010 - Aug 2011
Intern

Education:

Swiss Hotel Management School 2009 - 2011
Post graduate, Hospitality Zhejiang University 2007 - 2010
Zhejiang Wanli University 2005 - 2009
Bachelor of Arts (BA), Communication and Media Studies

Skills:

Hospitality Management